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Abstract
Alzheimer’s disease (AD) is characterized by the accumulation of extracellular amyloid β-protein (Aβ) and
intracellular hyperphosphorylated tau proteins. Recent evidence suggests that soluble Aβ oligomers elicit
neurotoxicity and synaptotoxicity, including tau abnormalities, and play an initiating role in the development of AD
pathology. In this study, we focused on the unclarified issue of whether the neurotoxicity of Aβ oligomers is a
reversible process. Using a primary neuron culture model, we examined whether the neurotoxic effects induced by
2-day treatment with Aβ42 oligomers (Aβ-O) are reversible during a subsequent 2-day withdrawal period. Aβ-O
treatment resulted in activation of caspase-3 and eIF2α, effects that were considerably attenuated following Aβ-O
removal. Immunocytochemical analyses revealed that Aβ-O induced aberrant phosphorylation and caspase-
mediated cleavage of tau, both of which were mostly reversed by Aβ-O removal. Furthermore, Aβ-O caused
intraneuronal dislocation of β-catenin protein and a reduction in its levels, and these alterations were partially
reversed upon Aβ-O withdrawal. The dislocation of β-catenin appeared to reflect synaptic disorganization. These
findings indicate that removal of extracellular Aβ-O can fully or partially reverse Aβ-O-induced neurotoxic alterations
in our neuron model. Accordingly, we propose that the induction of neurotoxicity by Aβ oligomers is a reversible
process, which has important implications for the development of AD therapies.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder characterized clinically by memory loss
and cognitive decline. Its major pathological hallmarks
are extracellular senile plaques and intracellular
neurofibrillary tangles, which are composed of amyloid
β-protein (Aβ) and phosphorylated tau (p-tau) protein,
respectively [1]. A central role of Aβ in the molecular
pathology of AD has been established [2]. Aβ is gener-
ated by sequential cleavages of amyloid precursor pro-
tein (APP) by β-site APP cleaving enzyme 1 (BACE1)
and γ-secretase [3]. Under pathological conditions, Aβ
self-aggregates to form Aβ oligomers, which likely
induce abnormalities of tau and cause cellular stress re-
sponses, including caspase activation and disturbances
of synaptic structure and plasticity. Thus, Aβ oligomers
are considered to be an initiator of AD pathology [4–7].
The mechanisms by which Aβ oligomers induce neuro-
toxicity, critical issues from a therapeutic standpoint,
remain to be elucidated, although several hypotheses
have been suggested [4–10]. The major theory is that
extracellular Aβ oligomers interact with certain cell
surface receptors to cause aberrant signal transduction.
Alternatively, it has been suggested that extracellular Aβ
oligomers disrupt the cell membrane directly or intracel-
lular Aβ oligomers elicit neurotoxicity. Although a link
between Aβ oligomers and tau has been established
[11, 12], signaling pathways linking the two remain
elusive. It also remains to be clarified whether the
neurotoxicity of Aβ oligomers is reversible and abates
upon their removal.
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We previously established a primary neuron culture
model in which Aβ oligomers trigger apparent neurotox-
icity with relatively modest neuronal death [13]. In the
current study, we took advantage of this system to investi-
gate the reversibility of Aβ oligomers-associated neurotox-
icity, characterized by caspase activation and tau
abnormalities. Here, we present evidence that the neuro-
toxicity of Aβ oligomers is reversible in primary neurons.
Results
Reversal of Aβ oligomer-induced caspase-3 and eIF2α
activation upon oligomer removal
We established a primary neuron culture model in
which treatment of neurons at 9 days in vitro (DIV9)
with 2.5 μM Aβ42 oligomers (Aβ-O) exert neurotoxic
effects with modest cell death [13]. In this model, Aβ-O
induces activation of caspase-3, a major apoptosis
marker, and eIF2α, a mediator of various stress re-
sponses [14]. During 3 days of Aβ-O treatment, a time-
dependent increase in cleaved caspase-3 levels was ob-
served, which corresponded to a time-dependent slight
decrease in cell survival [13], suggesting progression of
neuronal degeneration during the treatment period. We
inferred that the capacity of neurons to recover from the
Aβ-O-induced neuronal damage may be dependent on
the time period of Aβ-O exposure. In our pilot experi-
ments, neurons appeared to recover from caspase-3 acti-
vation and abnormal tau phosphorylation, the latter of
which is described in the following section, upon with-
drawal of Aβ from medium on day 2, whereas they did
not appear to recover considerably upon Aβ removal on
day 3. Therefore, we decided to investigate whether Aβ-
O neurotoxicity is reversible using the experimental
protocol depicted in Fig. 1a. Neurons were incubated
with or without Aβ-O for 2 days, at which point cells
were deprived of Aβ-O by replacing the medium with
fresh medium lacking Aβ-O, or were re-provided Aβ-O,
and cultured for an additional 2 days. We first estimated
the effects of Aβ-O on cell survival using a Cell Count-
ing Kit-8. Aβ-O treatment for 2 and 4 days decreased
neuronal viability by 12 and 30%, respectively, compared
with controls. Neuronal viability in the treatment group
in which Aβ-O was removed after 2 days was ~85% of
that in controls on day 4, a value significantly higher
than that of neurons treated continuously with Aβ-O for
4 days (Fig. 1b).
We next investigated whether cellular stress responses
to Aβ-O are reversible. Treatment of neurons with Aβ-
O induced a time-dependent increase in cleaved
caspase-3 levels on days 2 and 4 compared with controls
(Fig. 1c, d). Cleaved caspase-3 levels on day 4 in neurons
deprived of Aβ-O were significantly lower than those in
neurons treated continuously with Aβ-O for 4 days, and
were even lower than those on day 2 (Fig. 1c, d).
Treatment of neurons with Aβ-O also significantly in-
creased the ratio of phosphorylated to total eIF2α (p-
eIF2α/total eIF2α) compared with control neurons on
days 2 and 4 (Fig. 1e, f ). As was the case for cleaved
caspase-3 levels, the p-eIF2α/total eIF2α ratio in neurons
deprived of Aβ-O was significantly decreased on day 4
compared with that in neurons treated continuously
with Aβ-O for 4 days, and appeared lower than that on
day 2 (Fig. 1e, f ). These data indicate that removal of
extracellular Aβ-O reverses Aβ-O-induced activation of
caspase-3 and eIF2α.
Aberrant tau phosphorylation induced by Aβ-O treatment
is reversed upon oligomer removal
Recent evidence suggests a link between Aβ-O and tau
abnormalities [11, 12]. To analyze this linkage, we exam-
ined abnormal tau phosphorylation by immunocyto-
chemistry using antibodies specific for p-tau (AT8 and
PHF-1) or unphosphorylated tau (Tau-1). Total tau im-
munoreactivity was localized mostly in neurites (likely
axons) of neurons (Fig. 2a), and was slightly decreased
after 2 or 4 days of continuous exposure; this small de-
crease was largely eliminated in neurons deprived of Aβ-
O (Fig. 2e). p-Tau was similarly located in neurites of
neurons (Fig. 2b, c). Continuous Aβ-O treatment signifi-
cantly increased p-tau levels in neurons, measured as
the intensity of AT8 or PHF-1 signals normalized to that
of total tau, on days 2 and 4 compared with that in con-
trol neurons (Fig. 2a–c, e–g). In contrast, the intensity
of unphosphorylated Tau-1 immunoreactivity in neurons
continuously treated with Aβ-O was significantly re-
duced compared with that in control neurons on days 2
and 4 (Fig. 2d, h). Notably, in neurons deprived of Aβ-
O, both the intensity of p-tau immunoreactivity, revealed
by AT8 and PHF-1 signals, and the intensity of unpho-
sphorylated Tau-1 immunoreactivity, were restored to
levels similar to those in control neurons on day 4
(Fig. 2b–d, f–h).
A further analysis of tau phosphorylation by Western
blot analysis showed that relative levels of unphosphory-
lated tau (Tau-1) to total tau in Aβ-O-treated neurons
decreased on days 2 and 4 compared with controls, and
tended to recover upon Aβ-O withdrawal on day 4
(Additional file 1: Figure S1). Although AT8 and PHF1
unexpectedly failed to yield consistent results in Western
blotting, our findings collectively suggest that Aβ-O-
induced abnormalities of tau phosphorylation are revers-
ible upon oligomer removal.
Aβ-O-induced caspase cleavage of tau is reversed upon
oligomer removal
It is known that activated caspase mediates the truncating
cleavage of tau [15, 16]. To investigate whether Aβ-O af-
fects tau cleavage, we performed immunocytochemistry
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using an antibody specific for the caspase-cleaved form of
tau. A limited number of untreated neurons were immu-
nopositive for cleaved tau, but on days 2 and 4 following
treatment with Aβ-O, the percentage of cleaved-tau-
positive cells was notably increased compared with con-
trol neurons (Fig. 3a, b). Removal of Aβ-O substantially
reduced the proportion of cells positive for cleaved tau, re-
storing it to a value similar to that in controls on day 4
(Fig. 3a, b).
Aβ-O treatment causes abnormal alterations in β-catenin
that are partially reversible upon oligomer removal
It has been reported that AD pathology is associated
with disrupted Wnt/β-catenin signaling [17, 18]. β-
catenin also plays important roles in the regulation of
synaptic structures and plasticity [19, 20]. To investigate
the involvement of β-catenin in the neurotoxic mechan-
ism of Aβ-O, we first analyzed the intraneuronal
localization of β-catenin by immunocytochemistry. β-
catenin immunoreactivity was mainly observed in
punctate structures over neurites of control neurons,
suggesting synaptic localization, consistent with the role
of β-catenin in synaptic vesicle localization and pre-
synaptic assembly [19]. Continuous Aβ-O treatment de-
creased the intensity of β-catenin immunoreactivity in
neurons on days 2 and 4 compared with that in controls
(Fig. 4a, b). Interestingly, Aβ-O apparently induced a
dramatic change in the intraneuronal localization of β-
catenin; positive immunoreactivities were observed mainly
in neurites and neuronal soma with markedly reduced
punctate staining, implying a shift from synapses to neur-
ites and soma. Withdrawal of Aβ-O partially reversed the
Fig. 1 Effects of Aβ-O treatment and removal on caspase-3 and eIF2α in primary cortical neurons. a Experimental design. Primary neurons (DIV9)
were treated with 2.5 μM Aβ-O (O) or vehicle (C) for 2 days. On day 2, Aβ-O-treated neurons were washed and further treated with Aβ-O (O) or
deprived of Aβ-O (O-R) for an additional 2 days. Control neurons (C) were similarly cultured for an additional 2 days. b Cell survival assay. Cell
survival was analyzed by CCK-8 assay as described in Methods. The graph shows survival levels relative to those in controls on day 2 or 4. c Cells
were lysed on day 2 or 4, and cell lysates were analyzed by Western blotting using an anti-cleaved caspase-3 antibody. d Cleaved caspase-3 levels
were quantified and expressed relative to those in control neurons on day 2. e Cell lysates were analyzed by Western blotting using anti-eIF2α or
anti-p-eIF2α antibodies. f Total and p-eIF2α levels were quantified and expressed as p-eIF2α/total eIF2α ratios relative to those in control neurons
on day 2. Data represent means ± SEM from three separate experiments. *p < 0.05, **p < 0.01, compared with control. #p < 0.05, compared with
Aβ-O-treated cells
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decreased intensity of β-catenin immunoreactivity as well
as its abnormal intraneuronal localization on day 4 com-
pared with neurons treated continuously with Aβ-O
(Fig. 4a, b). We further analyzed the protein level of β-
catenin by Western blotting. β-catenin levels in control
neurons increased with the age of the culture and were
lower in Aβ-O-treated neurons than control neurons on
days 2 and 4 (Fig. 4c, d). Upon Aβ-O withdrawal, β-
catenin recovered to a level intermediate between those in
control and Aβ-O-treated cells (Fig. 4c, d). In addition,
continuous Aβ-O treatment induced a significant, time-
dependent reduction in the phospho-β-catenin (p-β-ca-
tenin)/total β-catenin ratio compared with controls on
days 2 and 4 that was partially reversed on day 4 by
removal of Aβ-O (Fig. 4c, e). To examine the relationship
between Aβ-O-induced β-catenin alterations and synapses,
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Fig. 2 Effects of Aβ-O treatment and removal on abnormal phosphorylation of tau. Primary neurons grown on coverslips were treated as in Fig. 1,
followed by immunofluorescence staining with anti-total tau (a), AT8 (b), PHF1 (c) or Tau-1 (d) antibodies. Scale bar = 20 μm. e-h Immunofluorescence
intensities were quantified as described in Methods, and expressed relative to those in controls on day 2 or 4. For AT8 (f), PHF-1 (g), and Tau-1 (h),
immunofluorescence intensity levels were normalized to those of total tau (e). Data represent means ± SEM from three separate experiments.
*p < 0.05, **p < 0.01, compared with control. #p < 0.05, compared with Aβ-O-treated cells
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we performed double immunostaining of β-catenin and
SNAP-25, a presynaptic SNARE protein [21]. We observed
that both proteins underwent similar alterations in intra-
neuronal localization following Aβ-O treatment (Additional
File 2: Figure. S2), implying that the abnormal alterations of
β-catenin are associated with disorganization of synapses.
Discussion
We have established a primary neuronal culture model
in which relatively low concentrations of Aβ-O induce
modest neuronal death. Our data showed that Aβ-O in-
duces activation of caspase-3 and eIF2α, and abnormal
phosphorylation and cleavage of tau. These abnormal al-
ternations have been reported to be present in AD
brains [11, 12, 14, 15, 22–24], suggesting that our model
reflects the characteristic features of AD pathology. Our
study also provides evidence of a direct link between
Aβ-O and tau abnormalities, in accord with previous
studies [25–30]. To evaluate whether Aβ-O neurotox-
icity is a reversible or irreversible process, we used an
experimental paradigm in which neurons exposed to
Aβ-O for 2 days were further treated with Aβ-O for 2
additional days or were deprived of Aβ-O for this same
culture period. We then compared control and Aβ-O–
treated neurons on day 2, and control, Aβ-O-treated and
Aβ-O–deprived neurons on day 4. We first focused on
caspase-3 and eIF2α, both of which are thought to be
important in mediating AD neurodegenerative processes
[15, 24]. We found that the levels of cleaved caspase-3
and p-eIF2α in Aβ-O-deprived neurons were much
lower on day 4 than those in neurons continuously
treated with Aβ-O, and were similar to those in controls.
These findings suggest that neurons can recover follow-
ing Aβ-O removal, even after neuronal injury responses
to Aβ-O have already progressed.
We examined the abnormal phosphorylation of tau by
detection with the antibodies AT8 and PHF-1, which
recognize major phosphorylation sites characteristic of
AD [31]. Immunocytochemically, AT8 and PHF-1 sig-
nals increased whereas unphosphorylated Tau-1 immu-
noreactivity decreased on days 2 and 4 in neurons
treated continuously with Aβ-O compared with those in
control neurons. Intriguingly, Aβ-O removal reversed
these alterations in AT8, PHF-1, and Tau-1 immunore-
activities. In considering possible mechanisms underlying
this recovery, we note that the phosphorylation sites rec-
ognized by AT8 and PHF-1 are known to be targeted by
the major tau kinases GSK3β and Cdk5 [32, 33]; thus, Aβ-
O-induced abnormal tau phosphorylation may be attribut-
able to activation of these kinases [31]. Accordingly, it is
possible that Aβ-O removal may induce deactivation of
these kinases, leading to dephosphorylation of tau at the
corresponding target sites. In addition, it is conceivable
that the activity of tau-targeted phosphatases also in-
creases following Aβ-O withdrawal.
Our analyses further demonstrated that Aβ-O treat-
ment increased the proportion of neurons positive for
cleaved tau on days 2 and 4, and showed that this effect
was fully reversed following Aβ-O deprivation for 2 days.
It is likely that Aβ-O induces tau cleavage through
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Fig. 3 Effects of Aβ-O treatment and removal on aberrant cleavage of tau. a Primary neurons grown on coverslips were treated as in Fig. 1,
followed by double-immunofluorescence staining with anti-cleaved tau (green) and anti-CREB (red) antibodies. Scale bar = 20 μm. b The
percentage of all CREB-positive cells positive for cleaved tau was calculated as described in Methods and graphed. Data represent means ± SEM
from three separate experiments. *p < 0.05, compared with control. #p < 0.05, compared with Aβ-O-treated cells
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caspase activation, since caspase-3 is known to cleave
tau at Asp421 [15]. Consistent with this view, the rever-
sal of tau cleavage paralleled with that of caspase-3 acti-
vation upon Aβ-O withdrawal. Recent studies have
suggested that cleaved tau is prone to aggregate and may
act as a seed for formation of aggregates [22], and that
caspase-mediated cleavage of tau initiates tangle forma-
tion [34]. Moreover, cleaved tau appears to be preferen-
tially released from neurons for possible interneuronal
transmission [35, 36]. Taken together, our findings that
abnormal phosphorylation and truncation of tau induced
by Aβ-O were reversed upon oligomer removal suggest
that these tau alternations are reversible processes. It
has been suggested that Aβ oligomers induce tau mis-
sorting from axons to dendrites [37, 38]. Further studies
are necessary to investigate whether such tau missorting
occurs in our model system.
We found that the localization pattern of β-catenin
was markedly altered by Aβ-O treatment, implying dis-
sociation of β-catenin from synapses. Further, β-catenin
levels were decreased in Aβ-O-treated neurons com-
pared with controls. We observed that Aβ-O removal re-
versed these abnormal β-catenin alterations, consistent
with the idea that Aβ-O–induced neuronal insults are
a
b
d
c
e
Fig. 4 Effects of Aβ-O treatment and removal on β-catenin in primary cortical neurons. a Primary neurons grown on coverslips were treated as in Fig. 1,
followed by immunofluorescence staining with an anti-β-catenin antibody. Bottom panel shows high-magnification images of the regions depicted by
white squares in upper images. Scale bar = 20 μm. b Immunofluorescence intensity of β-catenin staining was quantified as described in Methods and
expressed relative to levels in control neurons on day 2 or 4. Data represent means ± SEM from three separate experiments. c Primary neurons were
treated as in Fig. 1, followed by Western blot analysis of cell lysates using the indicated antibodies. d, e β-catenin (d) levels and p-β-catenin/total
β-catenin ratios (e) expressed relative to those in control neurons on day 2. Data represent means ± SEM from three separate experiments. *p < 0.05,
**p < 0.01, compared with control. #p < 0.05, ##p < 0.01, compared with Aβ-O-treated cells
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reversible. Aβ-O-induced β-catenin dislocation may be
associated with perturbation of synaptic organization.
This possibility is supported by our observation that
SNAP-25 was similarly dislocated upon Aβ-O treatment
(Fig. S2). Consistent with this, synapsin I, a representa-
tive presynaptic protein, and αN-catenin, a binding part-
ner of β-catenin [39], were observed to exhibit similar
abnormal dislocation following Aβ-O treatment (data
not shown). These observations are consistent with the
notion that Aβ oligomers disrupt synaptic structures and
functions in vitro and in vivo [4, 6, 7, 40].
Many reports have suggested that disturbances in
Wnt/β-catenin signaling are linked to AD [17, 18]. Aβ-
induced activation of apoptosis and synaptotoxicity are
reported to be antagonized by certain Wnt agonists such
as Wnt-3a, implying that Aβ disrupts Wnt signaling,
possibly through interaction with frizzled receptors
[41–45]. Since the Wnt signaling pathway negatively
regulates GSK3β [46], it is plausible that treatment
with Aβ oligomers inhibits Wnt/β-catenin signaling
and induces activation of GSK3β. In the canonical
Wnt signaling pathway, phosphorylation of β-catenin
by GSK3β facilitates β-catenin degradation [17, 18].
However, our finding that p-β-catenin levels were re-
duced by Aβ-O exposure suggests that the decrease
in β-catenin in our experimental system was inde-
pendent of β-catenin phosphorylation.
Several hypotheses have been suggested to account
for the mechanism by which Aβ oligomers induce
neurotoxicity [4–10]. One major model is that extra-
cellular Aβ oligomers interact with certain cell surface
receptors, resulting in aberrant signal transduction
[4–7, 10]. Alternatively, it has been suggested that Aβ
oligomers disrupt the cell membrane directly or that
intracellular Aβ oligomers cause neurotoxicity [8, 9].
Our demonstration that pathological alternations in-
duced by Aβ-O can be reversed by its extracellular
removal tends to favor the idea that Aβ-O neurotox-
icity is mediated by certain cell-surface proteins; thus,
at least under our experimental conditions, other
models appear unlikely (Fig. 5).
Our results indicate that neurotoxicity induced by Aβ
oligomers is a reversible process in that neurons are cap-
able of recovering from the moderate neurotoxic insults.
The present findings are consistent with a small number
of prior reports. Lee et al. [47] showed that the impair-
ment in synaptic activity induced by short-term treat-
ment with Aβ oligomers is reversible. Brikha et al. [48]
used mouse organotypic slices to show that Aβ-induced
spine loss recovers following Aβ washout. An in vivo
study using APP transgenic mice reported that Aβ-
associated neuritic dystrophy can be recovered by appli-
cation of anti-Aβ antibody [49]. More importantly, a re-
cent study reported that cognitive dysfunction in APP
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Fig. 5 Schema illustrating a possible mechanism by which neurotoxic effects of Aβ-O are reversed by its removal. Aβ-O possibly acts on the cell
surface of neurons to transmit aberrant signals, resulting in various abnormal cellular responses, including caspase-3 activation, eIF2α activation,
tau phosphorylation and cleavage, and abnormal subcellular localization of β-catenin and a reduction in its levels (upper schema, O). Caspase
activation is likely responsible for tau cleavage. The alterations of β-catenin may be associated with disorganization of synapses. Upon Aβ-O
removal, the aberrant signals subside, resulting in reversal of all abnormal responses (lower schema, O-R)
Tanokashira et al. Molecular Brain  (2017) 10:4 Page 7 of 10
transgenic mice is restored following suppression of the
transgene, an effect that was attributed to a reduction in
Aβ oligomers [50]. This in vivo observation appears to be
consistent with our in vitro findings, and suggests that any
treatment designed to remove or reduce Aβ oligomers
would be effective against AD. One example of such treat-
ments is immunotherapy targeting Aβ oligomers, which
has been shown to reduce Aβ burden and improve synap-
tic and cognitive deficits in animal models [51, 52]. Clin-
ical trials of passive immunotherapy using antibodies
specific for Aβ oligomers are in progress [53]. In addition,
the use of BACE1 inhibitors to prevent Aβ oligomer accu-
mulation is also a promising therapeutic option [54].
In summary, we investigated the reversibility of Aβ
oligomer-induced neurotoxicity, using a neuron model
system which reflects the characteristic features of AD
pathology. We demonstrated that Aβ-O treatment in-
duces activation of caspase-3 and eIF2α, aberrant
phosphorylation and caspase-mediated cleavage of tau,
and abnormal alterations in β-catenin, and showed that all
of these abnormalities were fully or partially reversed upon
extracellular removal of Aβ-O. These findings collectively
suggest that Aβ oligomers-associated neurotoxicity is a
reversible process, supporting the view that treatments
targeting Aβ oligomers have significant therapeutic poten-
tial for AD. Further studies on the molecular mechanisms
underlying the reversibility of Aβ oligomers-induced
neurotoxicity will contribute to the development of novel
therapeutic strategies to treat or prevent AD.
Methods
Cell culture
Primary neuronal cultures were prepared from cerebral
cortices of rat embryos at embryonic day 17, essentially
as described previously [13, 55]. Neurons were plated on
poly-L-lysine–coated plates or dishes at a density of 680
cells/mm2. Cells were maintained in a humidified
atmosphere of 5% CO2/95% air in Macs Neuro
Medium (Miltenyi Biotec, Auburn, CA, USA) containing
0.5 mM L-glutamine, NeuroBrew-21 (Miltenyi Biotec),
and penicillin-streptomycin. Half of the medium was
replaced with fresh medium every 3–4 days.
Aβ preparation and treatment
Aβ42 oligomers (Aβ-O) were prepared as described pre-
viously [13, 56]. Briefly, human Aβ(1–42) peptide (Pep-
tide Institute, Osaka, Japan) was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP; Sigma, St Louis, MO,
USA) in a chemical fume hood to obtain a 1 mM solu-
tion. HFIP was evaporated overnight in the hood and
further under vacuum for 1 h, and dried peptide films
were stored at –30 °C. Prior to use, a 5 mM stock was
prepared by dissolving dried Aβ peptide in dimethyl sulf-
oxide (DMSO), and sonicating it in an ultrasonic bath
sonicator for 10 min. Oligomers were prepared by diluting
5 mM Aβ DMSO stock to 0.1 mM with DMEM/F12 with-
out phenol red and left for 1 day at 4 °C. Immediately be-
fore addition to DIV9 neurons, Aβ-O preparations were
diluted to 2.5 μM with neuronal medium and used to re-
place the entire medium. Control cultures were treated
with the same concentration of DMSO [13]. After Aβ-O
treatment for 2 days, the cells were rinsed twice and incu-
bated with fresh medium with or without Aβ-O for an
additional 2 days (Fig. 1a).
Antibodies
The antibodies used were as follows: anti-cleaved caspase-
3 (Asp175) (Cell Signaling, Danvers, MA, USA); anti-eIF2α
(Assay Biotechnology, Sunnyvale, CA, USA); anti-p-eIF2α
(Ser51) (Cell Signaling); AT8, which recognizes tau protein
phosphorylated at Ser202 and Thr205 (Thermo Scientific,
Rockford, IL, USA); PHF-1, which recognizes tau phos-
phorylated at Ser396 and Ser404 [57] (provided by Dr.
Peter Davies); Tau-1, which recognizes unphosphorylated
epitopes between residues 192 and 204 (Millipore, Darm-
stadt, Germany); anti-cleaved tau (Asp421) (Millipore);
anti-total tau (E178, Abcam, Cambridge, MA, USA; Tau-5,
Thermo Scientific); anti-CREB (Gene Tex, Irvine, CA,
USA); anti-β-catenin (Cell Signaling); anti-p-β-catenin
(Ser33 + Ser37) (Abcam); anti-SNAP-25 (BioLegend, San
Diego, CA, USA) and anti-β-actin (Wako, Osaka, Japan).
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer containing protease inhibitors and phos-
phatase inhibitors, and cell lysates were prepared as de-
scribed previously [13]. For Western analysis of tau, cells
were lysed in sodium dodecyl sulfate (SDS) lysis buffer
(62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1 mM di-
thiothreitol, 5 mM EDTA) containing protease inhibitors
and phosphatase inhibitor cocktail, and heated at 95 °C
for 10 min, followed by centrifugation at 100,000 g for
30 min. Western blotting of cell lysates was performed
using a standard procedure, as described previously [13].
Protein band densities were quantified using an LAS-
1000 image analyzer (Fuji Film Co., Tokyo, Japan).
Cell survival assay
Cell survival assays were performed as described previ-
ously [13]. Briefly, primary cortical neurons cultured on
12-well plates were treated with Aβ-O or vehicle, as de-
scribed above. Cell Counting Kit-8 solution (Dojindo,
Kumamoto, Japan) was added to each well, and the
plates were left in a CO2 incubator for 2 h. Absorbance
was measured at 450 nm using a microplate reader. Ab-
sorbance of the medium, used as a blank, was subtracted
from that of each sample.
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Immunocytochemistry
Immunocytochemical analyses were performed as de-
scribed previously [13, 58]. Briefly, primary neurons
cultured on coverslips were fixed with 4% paraformalde-
hyde in phosphate-buffered saline (PBS). Fixed cells were
permeabilized and blocked with 0.3% Triton X-100 and
1% horse serum in PBS, and incubated with primary
antibody for 1 h, followed by incubation with Alexa488-
conjugated anti-mouse or anti-rabbit IgG secondary
antibodies (Molecular Probes, Eugene, OR, USA) for
1 h. For double-immunofluorescence staining, cells were
subsequently incubated with another primary antibody
and Alexa568-conjugated specific secondary antibody.
Specimens were observed under an LSM 780 laser-
scanning confocal microscope (Carl Zeiss, Jena,
Germany). Images illustrating antibody labeling were ac-
quired using a 20× 0.8 N.A. dry objective. The mean
fluorescence intensity of tau (E178), AT8, PHF-1 and
Tau-1 was quantified using the entire image (212.55 ×
212.55 μm) as the region of interest. In every immuno-
staining experiment, 4–5 images were analyzed for each
condition. The values for AT8, PHF-1 and Tau-1 were
normalized to that of tau (E178). Cleaved tau was ana-
lyzed in cells doubly immunostained with antibodies
against cleaved tau and CREB, the latter of which was
used to visualize viable neurons. The percentage of
CREB-positive neurons positive for cleaved tau in the
whole image was calculated. Five images were analyzed
for each condition in every experiment.
Statistical analysis
All results are presented as means ± SEMs. Data were
statistically analyzed using one-way analysis of vari-
ance (ANOVA) followed by a Tukey multiple com-
parison test or Student’s t-test with a significance
threshold of p < 0.05.
Additional files
Additional file 1: Figure S1. Western blot analysis of tau
phosphorylation. Primary neurons treated as in Fig. 1 were lysed in SDS
lysis buffer. Cell lysates were analyzed by Western blotting using anti-
total tau (Tau-5) and Tau-1 antibodies. Tau-1/Tau-5 ratios were expressed
relative to those in control neurons on day 2 or 4. Data represent means
± SEM from three separate experiments. *p < 0.05, compared with control.
#p < 0.05, compared with Aβ-O-treated cells. (PDF 1333 kb)
Additional file 2: Figure S2. The relationship between Aβ-O-induced
alterations of β-catenin and synapses. Primary neurons treated as in Fig. 1
were doubly immunostained with anti-β-catenin (green) and anti-SNAP-
25 (red). Similar alterations in intraneuronal localization of both proteins
were observed following Aβ-O treatment and removal. Evident co-
localization was not observable between the two proteins. (PDF 548 kb)
Abbreviations
AD: Alzheimer’s disease; Aβ: Amyloid β-protein; Aβ-O: Aβ42 oligomers;
DIV: Days in vitro; PBS: Phosphate-buffered saline; p-tau: Phosphorylated tau.
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